Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 26799419
Natarajan S, et al. (2016) High Mobility Group A2 protects cancer cells against telomere dysfunction. Oncotarget 7, 12761-82 26799419
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1981-p - ATM (human)
Modsite: sLAFEEGsQSTtIss SwissProt Entrez-Gene
Orthologous residues
ATM (human): S1981‑p, ATM (mouse): S1987‑p, ATM (rat): S1988‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  fibrosarcoma of soft tissue
Relevant cell lines - cell types - tissues:  HT1080 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HMGA2 (human) decrease HMGA2 low increase

S216-p - CDC25C (human)
Modsite: sGLyRsPsMPENLNR SwissProt Entrez-Gene
Orthologous residues
CDC25C (human): S216‑p, CDC25C iso3 (human): S173‑p, CDC25C (mouse): , CDC25C (frog): S287‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  fibrosarcoma of soft tissue
Relevant cell lines - cell types - tissues:  HT1080 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HMGA2 (human) decrease HMGA2 low increase

T68-p - Chk2 (human)
Modsite: SsLEtVstQELYsIP SwissProt Entrez-Gene
Orthologous residues
Chk2 (human): T68‑p, Chk2 iso9 (human): T68‑p, Chk2 iso11 (human): , Chk2 iso12 (human): T68‑p, Chk2 (mouse): T77‑p, Chk2 (rat): T76‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  fibrosarcoma of soft tissue
Relevant cell lines - cell types - tissues:  HT1080 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HMGA2 (human) decrease HMGA2 low increase

T230-p - TRF2 (human)
Modsite: HMSKDPttQkLRNDL SwissProt Entrez-Gene
Orthologous residues
TRF2 (human): T230‑p, TRF2 (mouse): T233‑p, TRF2 (rat): T188‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  fibrosarcoma of soft tissue
Relevant cell lines - cell types - tissues:  HT1080 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HMGA2 (human) decrease HMGA2 low increase